SynBiotic Resultados de beneficios anteriores
Pasado controles de criterios 0/6
SynBiotic's earnings have been declining at an average annual rate of -48.7%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 30.6% per year.
Información clave
-48.7%
Tasa de crecimiento de los beneficios
-37.7%
Tasa de crecimiento del BPA
| Crecimiento de la industria Pharmaceuticals | 7.3% |
| Tasa de crecimiento de los ingresos | 30.6% |
| Rentabilidad financiera | -76.6% |
| Margen neto | -275.3% |
| Última actualización de beneficios | 31 Dec 2023 |
Actualizaciones de resultados anteriores recientes
No hay actualizaciones
Recent updates
Desglose de ingresos y gastos
Cómo gana y gasta dinero SynBiotic. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Dec 23 | 4 | -11 | 3 | 0 |
| 31 Dec 22 | 8 | -24 | 6 | 0 |
| 31 Dec 21 | 9 | -13 | 2 | 0 |
| 31 Dec 20 | 5 | -1 | 1 | 0 |
| 31 Dec 19 | 0 | 0 | 0 | 0 |
Ingresos de calidad: SBX is currently unprofitable.
Margen de beneficios creciente: SBX is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: SBX is unprofitable, and losses have increased over the past 5 years at a rate of 48.7% per year.
Acelerando crecimiento: Unable to compare SBX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: SBX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Rentabilidad financiera
Alta ROE: SBX has a negative Return on Equity (-76.57%), as it is currently unprofitable.